Literature DB >> 9880623

Observer reliability in grading nephrocalcinosis on ultrasound examinations in children.

P T Dick1, B M Shuckett, B Tang, A Daneman, S W Kooh.   

Abstract

BACKGROUND: Nephrocalcinosis is often associated with a variety of hypercalcemic conditions. Diagnostic ultrasound is often used for assessing nephrocalcinosis in children, but its reliability has not been proven.
OBJECTIVE: To determine the reliability of expert interpretation of sonographic films with a grading scale of severity for nephrocalcinosis.
MATERIALS AND METHODS: Fifty-eight ultrasonographic films of 30 children with Williams syndrome and other conditions know to be associated with nephrocalcinosis were assessed. We used a blinded randomized design to assess intra- and interobserver reliability.
RESULTS: Grades I, II, and III nephrocalcinosis were noted in 13 %, 19 %, and 27 % of the examinations, respectively. The weighted kappa coefficient was 0.80 (standard error 0.12; 95 % confidence interval 0.68-0.92) for intraobserver agreement and 0.76 (standard error 0.13; 95 % confidence interval 0.63 to 0.89) for interobserver agreement. Reliability in assessing change from one examination to the next, with independently graded films, was fair with an unweighted kappa coefficient of 0.68 (95 % confidence interval 0.38-0.96) and 0.51 (95 % confidence interval 0.21-0.80) for intra- and interobserver reliability, respectively.
CONCLUSION: The severity of nephrocalcinosis can be reliably interpreted with an ultrasonography grading scale.

Entities:  

Mesh:

Year:  1999        PMID: 9880623     DOI: 10.1007/s002470050539

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  9 in total

1.  Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease.

Authors:  Renate Hueppelshaeuser; Gerd E von Unruh; Sandra Habbig; Bodo B Beck; Stephan Buderus; Albrecht Hesse; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2012-02-25       Impact factor: 3.714

2.  Nephrocalcinosis in Calcium Stone Formers Who Do Not have Systemic Disease.

Authors:  Naeem Bhojani; Jessica E Paonessa; Tariq A Hameed; Elaine M Worcester; Andrew P Evan; Fredric L Coe; Michael S Borofsky; James E Lingeman
Journal:  J Urol       Date:  2015-05-16       Impact factor: 7.450

3.  Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.

Authors:  Wesley Hayes; David J Sas; Daniella Magen; Hadas Shasha-Lavsky; Mini Michael; Anne-Laure Sellier-Leclerc; Julien Hogan; Taylor Ngo; Marianne T Sweetser; John M Gansner; Tracy L McGregor; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2022-08-01       Impact factor: 3.651

4.  Molecular Diagnosis of Primary Hyperoxaluria Type 1 and Distal Renal Tubular Acidosis in Moroccan Patients With Nephrolithiasis and/or Nephrocalcinosis.

Authors:  Abdouss Fatima; Ahakoud Mohamed; Hida Moustapha; Ouldim Karim
Journal:  Cureus       Date:  2022-03-29

Review 5.  Nephrolithiasis and Nephrocalcinosis in Childhood-Risk Factor-Related Current and Future Treatment Options.

Authors:  Alexander Weigert; Bernd Hoppe
Journal:  Front Pediatr       Date:  2018-04-12       Impact factor: 3.418

6.  Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy.

Authors:  Sarah M Barnett; Anthony H Jackson; Beth A Rosen; Jane L Garb; Gregory L Braden
Journal:  Kidney Int Rep       Date:  2018-02-21

Review 7.  Nephrocalcinosis in preterm neonates.

Authors:  Eveline A Schell-Feith; Joana E Kist-van Holthe; Albert J van der Heijden
Journal:  Pediatr Nephrol       Date:  2008-09-17       Impact factor: 3.714

Review 8.  Nephrocalcinosis: A Review of Monogenic Causes and Insights They Provide into This Heterogeneous Condition.

Authors:  Fay J Dickson; John A Sayer
Journal:  Int J Mol Sci       Date:  2020-01-06       Impact factor: 5.923

9.  Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1.

Authors:  Sally A Hulton; Jaap W Groothoff; Yaacov Frishberg; Michael J Koren; J Scott Overcash; Anne-Laure Sellier-Leclerc; Hadas Shasha-Lavsky; Jeffrey M Saland; Wesley Hayes; Daniella Magen; Shabbir H Moochhala; Martin Coenen; Eva Simkova; Sander F Garrelfs; David J Sas; Kristin A Meliambro; Taylor Ngo; Marianne T Sweetser; Bahru A Habtemariam; John M Gansner; Tracy L McGregor; John C Lieske
Journal:  Kidney Int Rep       Date:  2021-12-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.